AI Summary
Pharvaris (PHVS) will hold its AGM on June 26, 2026, with key pipeline catalysts on the horizon. The company anticipates topline data in Q3 2026 from the CHAPTER-3 trial of deucrictibant extended-release and progress updates from CREAATE in AAE-C1INH. Positive data or strategic updates could act as near-term catalysts for PHVS stock ahead of potential regulatory milestones.
Sentiment Rationale
Near-term catalysts (AGM and Q3 2026 CHAPTER-3 topline) can trigger price movement, particularly if data trends are favorable; historical biotech moves show outsized moves around topline readouts and pivotal trial updates, though results risk remains.
Trading Thesis
Bullish bias for PHVS ahead of Q3 2026 topline data and AGM, with potential moves in coming weeks to months on favorable results.
Market-Moving
- CHAPTER-3 topline data for deucrictibant extended-release expected in Q3 2026.
- CREAATE Phase 3 in prophylaxis/on-demand AAE-C1INH ongoing; topline data 2026.
- AGM on June 26, 2026 could yield new guidance or strategic updates.
- Marketing authorization filings for deucrictibant immediate-release capsule ongoing.
Key Facts
- AGM set for June 26, 2026, 16:00 CEST in Zug, Switzerland.
- CHAPTER-3 topline data for deucrictibant extended-release expected in Q3 2026.
- Deucrictibant on-demand HAE capsule; marketing authorization filings underway.
- CREAATE Phase 3 for AAE-C1INH ongoing; topline data anticipated in 2026.
Companies Mentioned
- Pharvaris (PHVS): Late-stage biopharma focusing on oral bradykinin B2 receptor antagonists; AGM and Q3 2026 data are near-term catalysts.
- Deucrictibant (drug candidate) (N/A): Immediate-release capsule for on-demand HAE; part of Pharvaris' Phase 3/registration programs.
Corporate Developments
Category: Corporate Developments. The article centers on an upcoming AGM and high-priority pipeline milestones, which are typical near-term corporate catalysts for a late-stage biotech stock like PHVS.